A study included 24 patients with metastatic NSCLC taking nivolumab, 19 of whom had CTCs with surface expression of PD-L1 at baseline and at 3 months of treatment and had poor outcomes, whereas patients with PD-L1-negative CTCs obtained clinical benefit at 6 months of treatment [127]. Here, CD274 is linked to non-small cell lung carcinoma.